Prostate-specific antigen cutoff of 2.6 ng/mL for prostate cancer screening is associated with favorable pathologic tumor features
Authors:
- Gustavo F CarvalhalGCGustavo F Carvalhal
- Christian G RamosCRChristian G Ramos
- Deborah S SmithDSDeborah S Smith
- Phataraporn ThorsonPTPhataraporn Thorson
- Yan YanYYYan Yan
- Peter A HumphreyPHPeter A Humphrey
- Kimberly A RoehlKRKimberly A Roehl
- William J CatalonaWCWilliam J Catalona
- 1 September 2002
- Vol. 60 (3) , 469-473
Abstract
No abstract availableKeywords
This publication has 23 references indexed in Scilit:
- Prostate cancer detection in men with serum PSA concentrations of 2.6 to 4.0 ng/mL and benign prostate examination. Enhancement of specificity with free PSA measurementsJAMA, 1997
- Prospective characterization of pathological features of Prostatic Carcinomas Detected Via Serum Prostate Specific Antigen Based ScreeningJournal of Urology, 1996
- The Pathological Features and Prognosis of Prostate Cancer Detectable With Current Diagnostic TestsJournal of Urology, 1994
- Pathologic and clinical findings to predict tumor extent of nonpalpable (stage T1c) prostate cancer1994
- Detection of organ-confined prostate cancer is increased through prostate-specific antigen-based screening1993
- Histologic grading of prostate cancer: A perspectiveHuman Pathology, 1992
- Measurement of Prostate-Specific Antigen in Serum as a Screening Test for Prostate CancerNew England Journal of Medicine, 1991
- Intraglandular tumor extent and prognosis in prostatic carcinoma: Application of a grid method to prostatectomy specimensHuman Pathology, 1990
- Prostate Specific Antigen in the Diagnosis and Treatment of Adenocarcinoma of the Prostate. II. Radical Prostatectomy Treated PatientsJournal of Urology, 1989
- Adenocarcinoma of the prostate in cystoprostatectomy specimens removed for bladder cancerCancer, 1989